0.00Open0.55Pre Close0 Volume329 Open Interest180.00Strike Price0.00Turnover7447.04%IV35.63%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier-7DDays to Expiry0.55Extrinsic Value100Contract SizeAmericanOptions Type-0.0307Delta0.0016Gamma506.84Leverage Ratio-695.0768Theta0.0000Rho-15.54Eff Leverage0.0004Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet